Cook launches new sizes of peripheral DES
This article was originally published in Clinica
Cook Medical has launched new sizes of its Zilver PTX drug-eluting peripheral stent, designed to treat peripheral artery disease in the superficial femoral artery, in Europe. The paclitaxel-coated device will now be available in lengths up to 120mm and with a 6 French diameter delivery system. Recently clinical data showed that the device causes a 50% reduction in restenosis compared with bare-metal stenting and allows 74.8% primary patency at two years (www.clinica.co.uk, 18 January 2011). Andy Förster, EMEA manager for Cook's peripheral intervention business unit, said: "Since the announcement of this data, adoption of the Zilver PTX has greatly increased." Zilver PTX is not yet approved in the US.
You may also be interested in...
Dr Noam Emanuel is the founder and chief technology officer of Ness Ziona, Israel-based drug delivery firm PolyPid. The 15-strong firm, established in 2008, has developed an encapsulation technology which allows the precise targeting of drug release.
Mesoblast has received the all-clear from the US FDA to start a Phase III clinical trial for bone marrow regeneration in patients with blood cancers. The study will be conducted together with Mesoblast's strategic alliance partner, Cephalon, which will fund the trial.
Mesoblast has received the green light from the US FDA to begin a Phase II trial of its proprietary adult mesenchymal precursor cell (MPC) product for the treatment of degenerative disc disease, a major cause of chronic low back pain.